AstraZeneca Pharma India share news and announcements
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
Formerly Astra IDL
Last close ₹5,988.50down ₹112.50 (1.84%)BSE ₹5,988.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹6,101.00.
52-week range of traded prices to 23 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,971 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 88.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 17.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.60%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,11847.8% delivered
AstraZeneca Pharma India board meetings
120 filed, newest first. Page 3 of 3.
Jul 2010
8 Jul · Board meeting
Inter alia, to consider seeking approval of Shareholders of the Company through postal ballot, pursuant to Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, in connection with the delisting proposal initiated by AstraZeneca Pharmaceuticals AB, Sweden, promoter of the Company.
Jun 2010
Apr 2010
15 Apr · Board meeting
Inter-alia, to consider and approve the unaudited financial results of the Company for the quarter ended March 31, 2010.
Mar 2010
25 Mar · Board meeting
At the meeting of the Board of Directors of the Company held on March 25, 2010, the Directors approved the following: (1) Proposal to augment the Company's Tablet manufacturing plant and facility involving an estimated aggregate outlay of Rs.70 Crores; (2) Appointment of Mr.Luigi Felice La Corte, as an Additional Director, on the Board of Directors of the Company. Further, the Company has submitted a copy of the updated list of the Board of Directors of the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Mar · Board meeting
Special meeting of the Board of Directors of the Company will be held on March 25, 2010, inter alia, to consider a proposal for augmenting the Company's existing manufacturing facility.
Feb 2010
23 Feb · Board meeting
At the Board Meeting of the Company held today i.e. February 23, 2010 the Directors approved / noted the following: (1) Change in Accounting Year : Approved the change in the accounting year of the Company from 'January-December' to 'April-March'. Accordingly, the next financial accounts and Annual Report shall be for a period of 15 months, i.e., from January 2010 to March 2011. (2) Change in Board of Directors: The Board noted the resignation of Mr. Bhasker V. Iyer, Director of the Company, with effect from February 23, 2010.4 Feb · Board meeting
Inter alia to consider and approve the Audited Financial Results of the Company for the last quarter and financial year ended December 31, 2009 and to recommend dividend, if any.
Oct 2009
5 Oct · Board meeting
Meeting on 27 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Jul 2009
10 Jul · Board meeting
Inter alia, to consider and approve the un-audited financial results of the Company for the quarter and half-year ended June 30, 2009.
Apr 2009
13 Apr · Board meeting
Meeting on 23 Apr 2009: “Unaudited Financial Results for the qtr ended March 31, 2009”
Feb 2009
3 Feb · Board meeting
Inter alia to consider and approve the Audited Financial Results of the Company for the last quarter and financial year ended December 31, 2008 and to recommend dividend, if any.
Oct 2008
7 Oct · Board meeting
Meeting on 23 Oct 2008: “Unaudited financial results for qtr ended September 30, 2008”
Jul 2008
10 Jul · Board meeting
Inter alia to consider and approve the Un-audited Financial Results of the Company for the quarter and half year ended June 30, 2008.
Apr 2008
3 Apr · Board meeting
Meeting on 28 Apr 2008: “Unaudited Financial Results for the qtr ended March 31, 2008”
Jan 2008
28 Jan · Board meeting
Inter-alia to consider and approve the audited annual accounts for the year ended December 31, 2007 and to recommend Dividend, if any.
Oct 2007
5 Oct · Board meeting
Meeting on 26 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Jul 2007
5 Jul · Board meeting
Inter alia to consider and approve the Unaudited Financial Results for the quarter and half year ended June 30, 2007.
Apr 2007
10 Apr · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the first quarter ended 31st March, 2007.
Mar 2007
9 Mar · Board meeting
To inter-alia consider the following business: 1) To consider revocation of recommended Dividend for the year ended December 31, 2006. 2) To consider payment of Interim Dividend for the year ended December 31, 2006, for which a Record Date of March 24, 2007 has been fixed. 3) To revise the Book Closure Dates fixed for the ensuing Annual General Meeting (AGM) scheduled on April 30, 2007 from April 23, 2007 - April 30, 2007 to April 27, 2007 to April 30, 2007 (both days inclusive). 4) To consider the approval of the revised Audited Accounts for the financial year ended December 31, 2006, after incorporating necessary changes as to the revocation of recommended dividend and payment of Interim Dividend for period ended December 31, 2006 and to make consequential changes in the Notice for the AGM and the Directors' Report.
Feb 2007
2 Feb · Board meeting
Inter-alia to consider and approve the audited annual accounts for the year ended 31st December, 2006 and to recommend Dividend, if any.